SpringWorks Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 305
- Market Cap
- $3B
- Website
- http://www.springworkstx.com
- Introduction
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
SW-682 in Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMesothelioma, Malignant
- Interventions
- Drug: Combination Therapy
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT06251310
- Locations
- 🇺🇸
SpringWorks Clinical Trial Site, Nashville, Tennessee, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Mirdametinib + BGB-3245 in Advanced Solid Tumors
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05580770
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Nirogacestat in Ovarian Granulosa Cell Tumors
- Conditions
- Ovarian CancerOvarian Granulosa-Stromal TumorOvarian Granulosa Cell Tumor
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05348356
- Locations
- 🇺🇸
UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Individual Patient Compassionate Use of Nirogacestat
- Conditions
- Desmoid TumorNOTCH Gene Mutation Positive Tumors
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Registration Number
- NCT05041036
Individual Patient Compassionate Use of Mirdametinib
- Conditions
- Neurofibromatosis Type 1-Associated Plexiform NeurofibromasHistiocytic NeoplasmOther MAP-K Pathway Driven Diseases
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Registration Number
- NCT05028166
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- Conditions
- Plexiform NeurofibromaNeurofibromatosis Type 1 (NF1)
- Interventions
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT03962543
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Nemours A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸University of California - Irvine Health, Orange, California, United States
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
- Conditions
- Aggressive FibromatosisDesmoid Tumor
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT03785964
- Locations
- 🇺🇸
Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States